One nagging concern about GLP-1 weight-loss drugs is that losing weight fast can also mean losing bone and muscle — potentially raising fracture risk. A large new analysis suggests the opposite may be true for semaglutide.
Presented at ENDO 2026, the Endocrine Society's annual meeting, the study found that in people with type 2 diabetes, semaglutide was associated with about a 15% reduction in bone fractures compared with other anti-obesity medications — alongside greater weight loss.
How big was it
The population-based study drew on the Atropos Health Eos electronic-health-record dataset representing roughly 161 million patients across U.S. hospitals and academic centers (2016–2023). It focused on adults with type 2 diabetes who had no prior fractures and weren't taking osteoporosis medications.
What it means
The finding “decouples” the traditional worry that weight-loss drugs weaken the skeleton, and points to a possible bone-protective effect — making semaglutide a potentially favorable option for diabetes patients at risk of fragile bones. But two caveats matter: this was presented at a conference (not yet peer-reviewed in a journal), and it's observational. The authors themselves recommend prospective studies to confirm it. This article is general information, not medical advice.